In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Theravance Biopharma (TBPH), with a price target of $55. The company’s shares closed yesterday at $22.87, close to its 52-week low of $21.04.
Chen noted:
“We rate TBPH 12-month price target of $55. We believe the Street is underestimating the peak sales potential of its key programs (JAK Inhibitor, TD-9855, Revefenacin, among others) and preclinical assets. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $55. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $55.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.8% and a 40.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Theravance Biopharma with a $47.50 average price target, which is a 107.7% upside from current levels. In a report issued on February 27, Needham also maintained a Buy rating on the stock with a $40 price target.
See today’s analyst top recommended stocks >>
Based on Theravance Biopharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $50.19 million. In comparison, last year the company had a GAAP net loss of $86.92 million.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Theravance Biopharma, Inc. operates as a biopharmaceutical company, which focuses on the discovery, development and commercialization of small molecule medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
